High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency

Peter Gergics; Cathy Smith; Hironori Bando; Alexander A. L. Jorge; Denise Rockstroh-Lippold; Sebastian Vishnopolska; Frederic Castinetti; Mariam Maksutova; Luciani Renata Silveira Carvalho; Julia Hoppmann; Julian Martinez Mayer; Frédérique Albarel; Debora Braslavsky; Ana Keselman; Ignacio Bergadá; Marcelo Martí; Alexandru Saveanu; Anne Barlier; Rami Abou Jamra; Michael H. Guo; Andrew Dauber; Marilena Nakaguma; Berenice B Mendonça; A Bilge Ozel; Qing Fang; Qianyi Ma; Jun Z. Li; Thierry Brue; María Ines Pérez Millán; Jacob O. Kitzman; Ivo JP Arnhold; Roland Pfaeffle; Sally A. Camper

doi:10.1101/2021.02.04.21249469

Abstract

Pituitary hormone deficiency occurs in ∼1:4,000 live births. Approximately 3% of the cases are due to mutations in the alpha isoform of POU1F1, a pituitary-specific transcriptional activator. We found four separate heterozygous missense variants in unrelated hypopituitarism patients that were predicted to affect a minor isoform, POU1F1 beta, which can act as a transcriptional repressor. These variants retain repressor activity, but they shift splicing to favor the expression of the beta isoform, resulting in dominant negative loss of function. Using a high throughput splicing reporter assay, we tested 1,080 single nucleotide variants in POU1F1. We identified 113 splice disruptive variants, including 23 synonymous variants. We evaluated separate cohorts of hypopituitarism patients and found two different synonymous splice disruptive variants that co-segregate with hypopituitarism. This study underlines the importance of evaluating the impact of variants on splicing and provides a catalog for interpretation of variants of unknown significance in the POU1F1 gene.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

National Institutes of Health (R01HD097096 to SAC), the Japan Society for Promotion of Science (HB), Grant 2013/03236-5 from the São Paulo Research Foundation (FAPESP) (IJPA), a grant from Pfizer (RP), and the Argentinean National Agency of Scientific and Technical Promotion, PICT 2016-2913 and PICT 2017-0002 (MIPM). There was no third party funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies were approved by ethical committees: the local Comite de Eticae Pesquisa da Faculdade de Medicina da Universidade de Sao Paulo (CEP-FMUSP) and the national Comite nacional de etica em pesquisa (CONEP) CAAE, 06425812.4.0000.0068; the Ethics Committee of the Faculty of Medicine, University of Leipzig (UL), Karl-Sudhoff-Institute for Medical History and Natural Sciences, Kaethe-Kollwitz-Strasse 82, 04109 Leipzig, Germany; and the Comite de Etica en Investigacion (Research Ethics Committee) of the Hospital de Ninos Ricardo Gutierrez (HNG), Gallo 1330, Ciudad autonoma de Buenos Aires, Argentina (CEI No. 16.06). The GENHYPOPIT network collected anonymized information in a database declared to health authorities in accordance with local regulations at Aix-Marseille Universite (AMU) - Conception Hospital (Assistance Publique - Hopitaux de Marseille, AP-HM), and a declaration was made to the National Commission for Data Protection and Liberties (CNIL-France): 1991429 v 0. The University of Michigan Institutional Review Board (UM) found the study exempt because patient DNA samples were anonymized before exome sequencing at UM.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes